Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
FDA warning letter
Pharma
Novo, Merck, Hengrui-Elevar—Fierce Pharma Asia
In two deals potentially worth $2 billion each, Novo gained a "triple G" candidate from United Labs as Merck bought a CV asset from Hengrui.
Angus Liu
Mar 28, 2025 9:28am
India's Aspen Biopharma Labs hit with FDA warning letter
Mar 26, 2025 1:09pm
Aspen Pharmacare hit with warning letter citing sterility issues
Mar 20, 2025 9:45am
Trump policy, Pfizer, CMIC—Fierce Pharma Asia
Mar 7, 2025 8:05am
Novo Nordisk, AstraZeneca, Ono—Fierce Pharma Asia
Feb 21, 2025 8:45am
FDA hits 2 Indian API makers with warning letters, import alerts
Feb 20, 2025 9:05am
